Prime Medicine obtained regulatory clearance from New Zealand’s Medsafe for its clinical trial application for PM-577a, a Prime Editor program targeting Wilson’s disease. The clearance advances the company toward dosing in a patient trial after earlier preclinical development. PM-577a is designed using Prime Editing, a genome-targeting approach intended to make precise DNA changes without relying on double-strand breaks typical of some CRISPR formats. For rare genetic liver diseases such as Wilson’s, the regulatory step is a key gating item for trial start timing. The development signal is particularly relevant for companies competing to translate base and prime editing concepts into clinical timelines, where site selection and regulatory readiness can determine pace. Prime Medicine’s progress will be closely watched by researchers focused on feasibility, durability, and delivery tolerability for editing therapies.